StreetInsider.com News Articles

Cantor Fitzgerald Reiterates Overweight Rating on Tyra Biosciences (TYRA)

Thu, 10 Sep 2026 09:26:12 -0400

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Tyra Biosciences (NASDAQ: TYRA).

The analyst commented, "Tyra reported the highly anticipated Ph2 SURF302 data in FGFR3+ IR-NMIBC. We also hosted Tyra's CEO Todd Harris for a fireside chat at our Cantor Healthcare Conference. At a high level, we believe the Phase 2 data substantially de-risk dabogratinib (dabo; FGFR3 inhibitor) not only in IR-NMIBC, but also in LG-UTUC—both of which could represent blockbuster opportunities. While the stock was weak (-18% vs. -1.2% for XBI), likely reflecting the headline 3-month CR rate (~60%) coming in below the ~70% target, we believe the

Tyra Biosciences reports Phase 2 data for oral bladder cancer drug

Wed, 09 Sep 2026 08:33:54 -0400

Tyra Biosciences (Nasdaq: TYRA) announced initial results from its Phase 2 SURF302 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC), according to a company statement.

As of an August 31, 2026 data cutoff, the 60 mg once-daily (QD) dose cohort showed a 79% overall response rate (ORR) and a 64% complete response (CR) rate as best overall response among combined single and multiple marker lesion patients (n=14). In single marker lesion patients receiving 60 mg QD (n=8), the ORR was 100% and the best overall response CR rate was 75%.

Safety data across

Tyra Biosciences reports Phase 2 data for oral bladder cancer drug

Wed, 09 Sep 2026 08:33:54 -0400

Safety data across

Tyra Biosciences reports Phase 2 data for oral bladder cancer drug

Wed, 09 Sep 2026 08:33:54 -0400

Safety data across

Tyra Biosciences reports Phase 2 data for oral bladder cancer drug

Wed, 09 Sep 2026 08:33:54 -0400

Safety data across

Piper Sandler Reiterates Overweight Rating on Tyra Biosciences (TYRA) Ahead of Dabo IR NMIBC Readout

Tue, 08 Sep 2026 09:22:22 -0400

Piper Sandler analyst Allison Bratzel reiterated an Overweight rating and $56.00 price target on Tyra Biosciences (NASDAQ: TYRA).

The analyst commented: "Dabo IR NMIBC Readout on Wednesday; We remain OW rated on TYRA shares ahead of proof-of-concept data for lead asset dabogratinib (selective FGFR3 inhibitor) in IR NMIBC, which is slated for disclosure the morning of Wednesday, September 9. As we've discussed previously (see data preview and here), we see the bar for success at this update as a 70% 3-month CR rate with relatively clean safety, which would facilitate advancement into a P3 trial in this setting. Supported by KOL

H.C. Wainwright Reiterates Buy Rating on Tyra Biosciences (TYRA)

Tue, 08 Sep 2026 07:54:21 -0400

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $45.00 price target on Tyra Biosciences (NASDAQ: TYRA).

The analyst commented: "Tyra scheduled an 8:00 a.m. Wednesday call/webcast with slides and several days’ notice for the initial Phase 2 SURF302 dataset. The company could have released the data Tuesday immediately after Labor Day or issued a press release without a call. We think management wants the data seen. We take the advanced notice and format as a sign of confidence. We expect ≥70% pooled three-month complete response (CR) across >20 patients in the 50mg and 60mg QD cohorts, with safety from

Form SCHEDULE 13G/A Tyra Biosciences, Inc. Filed by: NEXTECH VI ONCOLOGY SCSP

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932136.html

Form SCHEDULE 13G/A Tyra Biosciences, Inc. Filed by: NEXTECH VI ONCOLOGY SCSP

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932136.html

Form SCHEDULE 13G/A Tyra Biosciences, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Fri, 14 Aug 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26925047.html

Form SCHEDULE 13G/A Tyra Biosciences, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Fri, 14 Aug 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26925047.html

Tyra Biosciences (TYRA) PT Lowered to $42 at Jefferies

Wed, 05 Aug 2026 15:00:06 -0400

Jefferies analyst Stephen Volkmann lowered the price target on Tyra Biosciences (NASDAQ: TYRA) to $42.00 (from $44.00) while maintaining a Buy rating.

Tyra Biosciences, Inc. (TYRA) Misses Q2 EPS by 4c

Tue, 04 Aug 2026 17:46:45 -0400

Tyra Biosciences, Inc. (NASDAQ: TYRA) reported Q2 EPS of ($0.69), $0.04 worse than the analyst estimate of ($0.65).

For earnings history and earnings-related data on Tyra Biosciences, Inc. (TYRA) click here.

Form 424B5 Tyra Biosciences, Inc.

Tue, 04 Aug 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260804/26867604.html

Form 424B5 Tyra Biosciences, Inc.

Tue, 04 Aug 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260804/26867604.html

Form 10-Q Tyra Biosciences, Inc. For: Jun 30

Tue, 04 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260804/26867315.html

Form 10-Q Tyra Biosciences, Inc. For: Jun 30

Tue, 04 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260804/26867315.html

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tue, 04 Aug 2026 16:05:00 -0400

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5^th dose level, now expected end of Q1 2027 -

- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -

- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -

CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on